Intraosseous Infusion Devices Market

Intraosseous Infusion Devices Market: Overview

The Intraosseous Infusion Devices Market is valued at USD 6.2 Bn in 2026 and is projected to reach USD 10.2 Bn,  growing at a CAGR of 7% by 2033.The market size for the intraosseous infusion devices market was USD 829.5 million in 2021, and it is projected to grow at a CAGR of 5.1 percent during the forecast period. The prevalence of chronic conditions such as traumatic injuries, cardiovascular illnesses, obesity, and serious burns that increase the likelihood of hospitalization and the rise in emergency medical cases are the key drivers of the worldwide intraosseous infusion devices market's steady growth. Additionally, sedentary lifestyles severely impact human health and raise the risk of several conditions, including diabetes, urological disorders, end-stage renal disease, cardiovascular diseases, and chronic obstructive pulmonary disease. The over 97% success rate of intraosseous devices contributes to the market's expansion.

When peripheral venous access fails, and for cardiac resuscitation, the procedure of intraosseous infusion is advised. Over the assessment period, this aspect is anticipated to promote market expansion for intraosseous infusion devices worldwide. In the years to come, it is projected that rising rates of traumatic procedures performed in various hospital settings and cardiovascular disorders will drive market expansion for intraosseous infusion devices. C. R. Bard, Inc. was acquired by renowned U.S. medical technology corporation Becton, Dickinson and Company in December 2017. The oncology, urology, surgical, and vascular sectors all require medical technologies, and the latter has specialized in designing, producing, and selling these products. After the acquisition, the merged company is in a good position to offer patients better care and improve the care processes for healthcare service providers.

There is growing concern that, compared to medications, we tend to require far less evidence before implementing medical devices in clinic daily life10. This issue needs to be treated seriously, given the expenses involved and the potential effects of subpar equipment performance. In each Danish emergency room, the I.O. method was only applied five times a year on average, according to a study from Denmark11. Even in this situation, doing randomized research to compare I.O. devices would take years and more resources than necessary. Therefore, using other research setups for extremely uncommon operations, such as intraosseous access, seems fair.

Intraosseous Infusion Devices Market: COVID-19 Impact

Due to COVID-19, the market growth for intraosseous infusion devices has gradually increased. The number of emergency medical services requiring prompt care has increased during the epidemic. Furthermore, I.O. devices aid in the quick infusion of fluids and medications in clinical circumstances that require immediate care or attention, such as serious burns, accidents, or trauma where IV access is not currently accessible. As a result, the need for I.O. devices has increased. According to Narayana Health Organization, stroke can be a symptom of COVID-19, and 0.9% to 23% of COVID-19 patients experienced a stroke. In individuals with Covid-19, hemorrhagic and ischemic strokes are the two most common forms.

Intraosseous Infusion Devices Market: Drivers

Rising Demand for Emergency Healthcare has helped Intraosseous Infusion Devices Market to Grow Rapidly

I.O. Devices aims to minimize treatment time while maximizing efficiency, safety, and services. Sedentary behavior has also influenced the market's expansion because it contributes to several illnesses, such as end-stage renal diseases, COPD, urological disorders, cardiovascular diseases, etc. These persistent clinical circumstances have increased the demand for vascular access devices in the projection period. Emergency medical treatment is regarded as pre-hospital or ambulatory transportation assistance for victims of traffic accidents and individuals who have suffered serious injuries that call for quick medical attention. Ineffective medical care results from a lack of structural models in medical aid. The market for intraosseous infusion devices is supported by these reasons and the rising number of emergencies worldwide, which is predicted to increase the need for effective emergency medical services.

Rising Number of Traumatic Surgeries has helped Intraosseous Infusion Devices Market to Grow Rapidly

Community care consists of two parts: care provided during transit and inside a medical facility. When a patient is brought into an emergency room with a severe life-threatening condition, such as severe burns, a car accident, or cardiac arrest, it can be challenging to locate an IV point or difficult when the venous system has collapsed. Devices for intraosseous infusion are consequently needed on the market. More traumatic procedures have been reported in recent years, particularly in children, which is anticipated to support the market expansion for intraosseous infusion devices. According to the Royal College of Surgeons, 2019, a document on emergency surgery policy briefing shows that 32% of trauma and orthopedic surgery combined and 25% of patients were hospitalized in an emergency in 2012–2013. From 2002-03 to 2018-19, the rate of patient readmission increased by 27.1%.

Intraosseous Infusion Devices Market: Restraints

Side Effects of I.O. Combined with Growing Concern for Overuse of I.O. Procedure is Hampering Market Growth of Intraosseous Infusion Devices Market

IO is one of a few emergency therapy operations that are both highly uncommon and life-saving; other examples are emergency tracheostomy and emergency needle decompression9. The question is how novel methods and tools for such uncommon emergency operations should be assessed. There is growing concern that, compared to medications, we tend to require far less evidence before implementing medical devices in clinic daily life10. This issue needs to be treated seriously, given the expenses involved and the potential effects of subpar equipment performance. In each Danish emergency room, the I.O. method was only applied five times a year on average, according to a study from Denmark11. Even in this situation, doing randomized research to compare I.O. devices would take years and more resources than necessary. Therefore, using other research setups for extremely uncommon operations, such as intraosseous access, seems fair.

Intraosseous Infusion Devices Market: Segment Overview

Automatic Segment Dominated Market Due to Fewer chances of Mistake

Experts claim that the evidence to support the choice of an intraosseous (I.O.) insertion device is limited to observational studies and a few trials that vary depending on the patient's age, location (e.g., pre-hospital, hospital), clinical provider (e.g., paramedic, medic, physician), and clinical provider type (pediatric or adult). Regardless of the selected intraosseous insertion technique, thorough training is necessary before usage to increase the possibility of successful I.O. cannulation. Jamshidi (Cardinal Health) and the modified Dieckmann are examples of manual I.O. needles (Cook Critical Care). Due to the trocar feature, which consists of a short needle length with a handle that provides a resting spot for the palm and an adjustable flange or depth marking to guide placement, these are frequently employed in I.O. access operations. In the I.O. devices market, automation was found to be the largest market segment in 2020. EZIO includes a lithium-powered battery driver and needle sets in three lengths for use on kids and adults.

EZ-IO Segment Dominated Market Due to Effective Use will Drive The Market Growth

Intraosseous infusion (I.O.) is the medication delivery technique carried out directly into the bone marrow to provide a point of entry into the systemic venous system. This method can administer fluids and medications when intravenous access is unavailable or impractical. Adults' needs for I.O. infusion are growing during the administration of drugs and fluids during early resuscitation. When peripheral venous access is difficult to achieve, I.O. infusion should be used in all life-threatening circumstances. A few infrequent, usually usage-related issues are also present with these devices. With a bioavailability comparable to intravenous administration, the I.O. infusion enables blood sampling and the delivery of almost all fluids and drugs, including vasopressors. By product type, the intraosseous devices market was dominated by EZ-IO products.

Intraosseous Infusion Devices Market: Regional Landscape

North America to Dominate Market due to Rising Use of I.O. Devices in Ambulatory and Emergency Cases

Due to the rising use of I.O. devices in ambulatory and emergency cases, rising prevalence of various chronic diseases, rising number of traumatic surgeries, and military consumption being high, especially in times of war, North America was found to be the leading geographical region in the intraosseous devices market in the base year 2020. Market analysts claim that I.O. infusion is a quick, safe, and efficient method of gaining vascular access through the bone marrow when an intravenous attempt fails. 90% of U.S. advanced life support ambulances, more than half of U.S. emergency rooms, and the U.S. military use the EZ-IO. The U.S. military had 13,000 medics and 26,000 combat lifesavers with six and three intraosseous units (EZ-IO), respectively, during the Gulf War, according to a report by Vidacare Corporation, and a total of 160,000 intraosseous devices were anticipated to be employed.

With increasing I.O. device use, Asia-Pacific was identified as having the highest potential for intraosseous device markets. Pyng Medical Corp. has announced the major addition of India to the Asia-Pacific markets as part of the expansion of its exclusive dealer network globally. According to market analysts, there is a significant market for high-caliber medical gadgets developed in North America in India. Pyng's leadership in the Indian military, E.M.S., and hospital markets will be based on its dominance in Sternal I.O. for deployed U.S. military personnel. However, the business in this area is being constrained by high costs, a lack of ongoing training for medical and nursing staff, and clearly defined guidelines surrounding proper device management.

Intraosseous Infusion Devices Market: Competitive Landscape

For the Piper Go-IO Intraosseous Infusion System, Piper Access, L.L.C. got FDA 510(k) clearance in November 2019. Aero Healthcare purchased Clayton First Aid in July 2020, opening the door for them to diversify into intraosseous infusion devices. The purchase of Whitaker Park Development Authority Inc., which formerly produced cigarettes but would now produce intraosseous infusion devices for enhanced patient care, was announced by Cook Medical Incorporated on December 18, 2021.

Some Intraosseous Infusion Devices Market players include 

• Teleflex Incorporated (Arrow® EZ IO)
• Zoll Medical Corporation
• Vidacare (now part of Teleflex)
• Braun Melsungen AG
• Smiths Medical (ICU Medical)
• Cook Medical
• RFD Medical
• Nipro Medical Corporation
• Cardinal Health, Inc.
• Parker Medical, Inc.
• Vygon Group
• Werfen (Instrumentation Laboratory)
• Medtronic plc
• BD (Becton, Dickinson and Company)
• Microvena

Global Intraosseous Infusion Devices Market Segmentation is Described Below:

Type

• Manual IO Needles
• Battery Powered Driver
• Impact Driven Devices

End-use

• Hospitals and Clinics
• Ambulatory Surgical Centers
• Others

Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa